Astrazeneca (AZN) Interest & Investment Income (2009 - 2026)

Astrazeneca (AZN) has reported Interest & Investment Income for 18 consecutive years, with $73.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 13.1% year-over-year to $73.0 million; the TTM figure through Mar 2026 stood at $361.0 million (down 16.24% YoY), while the FY2025 annual figure was $360.0 million, down 21.4% from the prior year.
• Interest & Investment Income came in at $73.0 million for Q1 2026 at Astrazeneca, down from $135.0 million in the prior quarter.
• The five-year high for Interest & Investment Income was $183.0 million in Q3 2024, with the low at $15.0 million in Q3 2022.
• Average Interest & Investment Income over 5 years is $79.4 million, with a median of $78.0 million recorded in 2023.
• Across the five-year window, Interest & Investment Income jumped 4400.0% in 2022 and sank 53.55% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $45.0 million in 2022, then surged by 140.0% to $108.0 million in 2023, then slumped by 40.74% to $64.0 million in 2024, then jumped by 110.94% to $135.0 million in 2025, then slumped by 45.93% to $73.0 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $73.0 million, $135.0 million, and $85.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.